1
|
Bytyqi-Damoni A, Genç H, Zengin M, Beyaztas S, Gençer N, Arslan O. In vitroeffect of novel β-lactam compounds on xanthine oxidase enzyme activity. ACTA ACUST UNITED AC 2012; 40:369-77. [DOI: 10.3109/10731199.2012.678943] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
2
|
PU XY, LIANG JP, SHANG RF, WANG XH, WANG ZX, HUA LY, LIU Y. Influence of Hypericum perforatum Extract on Piglet Infected with Porcine Respiratory and Reproductive Syndrome Virus. ACTA ACUST UNITED AC 2009. [DOI: 10.1016/s1671-2927(08)60272-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
3
|
|
4
|
You ZL, Shi DH, Zhu HL. The inhibition of xanthine oxidase by the Schiff base zinc(II) complex. INORG CHEM COMMUN 2006. [DOI: 10.1016/j.inoche.2006.03.023] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
Pèpe G, Meyer M, Faury P, Graciet JC, Chermann JC, Kraus JL. A model allowing the design of modified nucleosides as HIV-RT inhibitors. Eur J Med Chem 1996; 31:775-86. [DOI: 10.1016/0223-5234(96)83971-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/1996] [Accepted: 03/18/1996] [Indexed: 11/17/2022]
|
6
|
Clayette P, Moczar E, Mabondzo A, Martin M, Toutain B, Marcé D, Dormont D. Inhibition of human immunodeficiency virus infection by heparin derivatives. AIDS Res Hum Retroviruses 1996; 12:63-9. [PMID: 8825620 DOI: 10.1089/aid.1996.12.63] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Heparin (Hep) and sulfated polysaccharides (SPs) have been reported to inhibit HIV infection in vitro. In vivo, anticoagulant activity and reduced bioavailability were found to limit the antiviral effects of Hep. In this investigation, three nonanticoagulant N-acylated Hep conjugates [OI1:3Hep, Pal1:5Hep, and Pal1:5Hep(SO4)] were compared to Hep for their ability to interact with HIV replication in CD4-positive cell lines and PBMCs. Resulfated palmitoyl-Hep [Pal1:5Hep(SO4)] exhibited the strongest anti-HIV effects. For instance, no provirus HIV DNA was detected in the genome of HIV-1-LAI-infected PBMCs treated with this heparin derivative. Cell-to-cell fusion and RT activity were explored to explain these differences. Hep and Pal1:5Hep(SO4) derivative exerted identical effects on cell-to-cell fusion. On the other hand, Pal1:5Hep(SO4) displayed the strongest inhibitory effects in the acellular RT inhibition assay. This suggests that RT might be a second target for N-acylated Hep, even though SP uptake and the preferential effects of SPs on RT as opposed to DNA polymerase have not yet been demonstrated. Nevertheless, considering the anticoagulant, antiviral, and antiinflammatory effects of N-acylated Hep, the N-acylated Hep derivatives might be excellent candidates as new anti-HIV pharmacological tools.
Collapse
Affiliation(s)
- P Clayette
- Commissariat à l'Energie Atomique, Centre de Recherches du Service de Santé des Armées, Fontenay-aux-Roses, France
| | | | | | | | | | | | | |
Collapse
|
7
|
|
8
|
Abstract
Part I of this article reviewed the targets against which anti-HIV drugs can be directed, problems in assessing active compounds (e.g. resistance development and use of surrogate end-points). and nucleoside analogues effective against HIV reverse transcriptase. Intensive research is currently being undertaken in laboratories and hospitals to design and evaluate new inhibitors of HIV. In this work, combining different drugs is one important approach, both to decrease toxicity and to offset the rate of resistance development, which seems to be a major problem associated with therapy directed against the ever-changing HIV. Therapeutic vaccines and immunomodulators are other modalities being actively evaluated against HIV and AIDS, although this effort has not yet yielded any licensed treatment. It appears likely that new antiviral drugs and immunotherapies will be forthcoming during the next 5 years, that they will be used in a variety of combinations, and that the treatment options available for opportunistic infections will increase. These developments should improve the survival and the quality of life of patients with HIV infection.
Collapse
Affiliation(s)
- E Sandström
- Department of Dermatovenerology, Södersjukhuset, Stockholm, Sweden
| | | |
Collapse
|
9
|
Rideout D, Schinazi R, Pauza CD, Lovelace K, Chiang LC, Calogeropoulou T, McCarthy M, Elder JH. Derivatives of 4-amino-3,6-disulfonato-1,8-naphthalimide inhibit reverse transcriptase and suppress human and feline immunodeficiency virus expression in cultured cells. J Cell Biochem 1993; 51:446-57. [PMID: 7684385 DOI: 10.1002/jcb.2400510410] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
We have developed a series of 4-amino-3,6-disulfonato-1,8-naphthalimide (ADSN) derivatives in an attempt to create nontoxic compounds effective against lentivirus infections. The ADSN derivative Lucifer Yellow CH ([N-(hydra zinocarbonyl)amino]-4-amino-3,6-disulfonato-1,8-naphthalimid e) (LYCH) was chosen as a parent compound because of its low toxicity in vivo and in vitro and its tendency to accumulate in monocyte/macrophages, a major reservoir for lentiviruses in vivo. Several ADSN derivatives inhibited reverse transcriptases (RTs) from human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus (FIV). Viral expression in HIV-infected human peripheral blood mononuclear cells was inhibited by noncytotoxic concentrations of two ADSN derivatives, designated A4 (biphenyl-4,4'-dicarboxaldehyde, Lucifer Yellow CH monohydrazone; EC50 = 29 microM after 6 days) and H4 (biphenyl-4,4'-dicarboxaldehyde, Lucifer Yellow CH dihydrazone; EC50 = 5.61 microM). A4 effectively suppressed the expression of FIV in infected Crandall feline kidney fibroblasts (CRFK) at 46.2 microM, reducing the RT levels by 97% after 19 days under conditions allowing direct cell-to-cell transmission of the virus. The viability of drug-treated FIV-infected CRFK cells increased significantly in the presence of A4 relative to the viability of untreated virus-infected cells. In contrast to A4 and H4, LYCH (which lacks the appended aromatic rings characteristic of A4 and H4) had no inhibitory effects on either virus and did not inhibit RT ex vivo. However, flow cytometry studies showed that both A4 and LYCH accumulate in two cell types that can support lentiviral infections: U937 human monocytic leukemic cells that have been induced to differentiate by using tetradecanoyl phorbol acetate, and CRFK cells.
Collapse
Affiliation(s)
- D Rideout
- Department of Molecular Biology, Research Institute of Scripps Clinic, La Jolla, California 92037
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Ljungdahl-Ståhle E, Guzenda E, Böttiger D, Wahren B, Oberg B, Ståhle L. Penetration of zidovudine and 3'-fluoro-3'-deoxythymidine into the brain, muscle tissue, and veins in cynomolgus monkeys: relation to antiviral action. Antimicrob Agents Chemother 1992; 36:2418-22. [PMID: 1489185 PMCID: PMC284346 DOI: 10.1128/aac.36.11.2418] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Cynomolgus monkeys had microdialysis probes implanted under ketamine anesthesia into peripheral veins, thigh muscles, and the brain in order to sample the extracellular fluid for the concentrations of unbound nucleoside analogs. A dose of 25 mg of zidovudine or 3'-fluoro-3'-deoxythymidine (FLT) per kg was administered subcutaneously to each of three animals. Relatively high antiviral concentrations of FLT and zidovudine were present in peripheral tissues and in the brain. It was found that the concentration of zidovudine in the brain was approximately one-third of that in muscle and veins; the same relation was observed for FLT. The in vivo unbound concentrations of both drugs in the brain, muscle, and venous blood exceeded those reported to inhibit human immunodeficiency virus replication in vitro. In addition, in a correlative study we found that the appearance of p24 antigen in sera of monkeys infected with simian immunodeficiency virus was significantly delayed by both compounds (15 mg/kg three times daily for 9 days after infection). Thus, we have shown that the extracellular concentrations of unbound FLT and zidovudine in the brain and peripheral tissues attained with in vivo antiviral doses exceed in vitro antiviral concentrations.
Collapse
|
11
|
Wiltink EH. Future prospects in antiviral therapy. PHARMACEUTISCH WEEKBLAD. SCIENTIFIC EDITION 1992; 14:268-74. [PMID: 1437509 DOI: 10.1007/bf01962549] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Two important stumbling blocks to the development of effective and nontoxic antiviral drugs are the intracellular localization of the virus and the fact that a virus uses host cell functions to multiply. Therefore, new antiviral drugs must act on a virus-specific function. Most currently available useful antiviral drugs are the result of compound screening of large numbers of possible agents. Advances in our understanding of the molecular biology and biochemistry of the viral multiplication cycle and new laboratory techniques for determining the molecular sites of action have now made it possible to develop and screen new antiviral drugs in a more purposeful manner. Another possible option in antiviral therapy is combination therapy using drugs that enhance the therapeutic effect or diminish side-effects. The most promising new antiviral drugs are discussed according to the different steps they affect in the viral multiplication process. Combination therapy is also reviewed.
Collapse
Affiliation(s)
- E H Wiltink
- Medical Centre, Department of Pharmacy, Amsterdam, The Netherlands
| |
Collapse
|
12
|
Hansen JE, Nielsen C, Svenningsen A, Witzke N, Mathiesen LR. Synergistic antiviral effect in vitro of azidothymidine and amphotericin B methyl ester in combination on HIV infection. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 1992; 24:35-9. [PMID: 1589723 DOI: 10.3109/00365549209048398] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The nucleoside analogue azidothymidine (AZT) and the methyl ester of amphotericin B (AME) were assayed for antiviral effect on HIV infection singly and in combination. Both compounds were effective in inhibiting HIV infection of MT-4 cells. At concentrations where either compound alone had no significant effect on infection, the compounds in combination were potent inhibitors of HIV as evaluated by reduction in HIV antigen production and HIV induced cytopathic effect. These results indicate that a combination therapy employing compounds with different modes of action like AZT and AME may have synergistic antiviral properties. Amphotericin B itself significantly reduced HIV infectivity in vitro and should not be used as an antifungal agent in cultures intended to propagate HIV.
Collapse
Affiliation(s)
- J E Hansen
- Department of Infectious Diseases, Hvidovre Hospital, Denmark
| | | | | | | | | |
Collapse
|
13
|
Yu S, Beese G, Keay BA. An improved synthesis of 2-substituted-3-furoic acids leading to an intramolecular Diels–Alder reaction between a dienophile and furan diene both containing an electron withdrawing group. ACTA ACUST UNITED AC 1992. [DOI: 10.1039/p19920002729] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
14
|
The Pharmacologic Treatment of HIV Infection and AIDS in Adults. Nurs Clin North Am 1991. [DOI: 10.1016/s0029-6465(22)00249-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
15
|
Abstract
There are only a limited number of effective, non-toxic antiviral drugs for clinical use, whereas there is a great need for such drugs. Especially for the treatment of patients infected with the human immuno-deficiency virus (HIV) anti-HIV drugs are required. At the same time viral infections secondary to AIDS cannot yet be treated effectively. An increasing problem is the development of virus strains resistant to the available drugs. At this moment a great effort is made in the research for new antiviral drugs. In this article the available antiviral drugs are reviewed. Their antiviral properties, mechanism of action, clinical use, pharmacokinetic properties and side-effects are discussed. Some attention is paid to the future directions in the search for new anti-HIV drugs.
Collapse
Affiliation(s)
- E H Wiltink
- Department of Pharmacy, University of Medical Centre, Amsterdam, The Netherlands
| | | |
Collapse
|
16
|
Christ W, Esch B. [Use-risk consideration of anti-infective agents from the point of view of the licensing authority]. Infection 1991; 19 Suppl 1:S65-71. [PMID: 2007519 DOI: 10.1007/bf01644739] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The present standard requirements for the clinical evaluation of anti-infective drugs are so high that in most cases strong evidence for the benefit of a new medicine can be provided. Therefore risk estimation is much more emphasized than proof of efficacy during the review process performed by the regulatory authority. The total number of patients treated with an investigational drug before an application is made for a product licence varies between 2,000 and 4,000; in rare instances up to 9,000 patients are evaluable. It is obvious that adverse effects with incidences of 0.5% cannot be detected during clinical investigation, even with such a great number of patients. The risk estimation of a new anti-infective drug is based on results from the following sources: toxicity studies in animals, studies on general pharmacology (preclinical and clinical), clinical studies on safety and efficacy, finger-print of adverse reactions of new compounds belonging to approved chemical classes, experience in other countries, and monitoring of safety after licensing. As many drugs share chemical or pharmacological characteristics with approved drugs, the pattern of adverse effects can be anticipated. When reviewing a new anti-infective agent not belonging to an approved chemical class, there remains more uncertainty. In the case of infections for which current treatment exists, the possible risks which can be accepted for a new compound cannot be higher than that of the alternatives. If no alternatives exist, in certain cases high risks can be accepted, especially when a potentially life-saving or life-prolonging drug is being evaluated. Among the adverse effects which cannot be anticipated are: hypersensitivity, ocular toxicity and CNS reactions.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- W Christ
- Institut für Arzneimittel des Bundesgesundheitsamtes, Berlin, Germany
| | | |
Collapse
|
17
|
Johnson VA, Hirsch MS. New developments in combination chemotherapy of anti-human immunodeficiency virus drugs. Ann N Y Acad Sci 1990; 616:318-27. [PMID: 2078026 DOI: 10.1111/j.1749-6632.1990.tb17852.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- V A Johnson
- Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston 02114
| | | |
Collapse
|
18
|
Chapter 16. Recent Advances in Anti-retroviral Chemotherapy for AIDS. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 1990. [DOI: 10.1016/s0065-7743(08)61592-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register]
|